143 related articles for article (PubMed ID: 34090063)
1. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
Wu X; Lu H; Pang T; Li X; Luo H; Tan H; Liu S
Leuk Res; 2021 Sep; 108():106605. PubMed ID: 34090063
[TBL] [Abstract][Full Text] [Related]
2. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
[TBL] [Abstract][Full Text] [Related]
3. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis.
Zhou Y; Chen H; Tao Y; Zhong Q; Shi Y
J Cancer; 2021; 12(2):553-561. PubMed ID: 33391451
[No Abstract] [Full Text] [Related]
4. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
[TBL] [Abstract][Full Text] [Related]
6. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
7. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC; Avet-Loiseau H; Anderson KC; Neri P; Paiva B; Samur M; Dimopoulos M; Kulakova M; Lam A; Hashim M; He J; Heeg B; Ukropec J; Vermeulen J; Cote S; Bahlis N
Blood Adv; 2020 Dec; 4(23):5988-5999. PubMed ID: 33284948
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
9. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
10. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.
Berry DA; Zhou S; Higley H; Mukundan L; Fu S; Reaman GH; Wood BL; Kelloff GJ; Jessup JM; Radich JP
JAMA Oncol; 2017 Jul; 3(7):e170580. PubMed ID: 28494052
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
[TBL] [Abstract][Full Text] [Related]
12. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
[TBL] [Abstract][Full Text] [Related]
13. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
14. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
[TBL] [Abstract][Full Text] [Related]
15. Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
Zhang W; Jang E
PLoS One; 2021; 16(8):e0256801. PubMed ID: 34437635
[TBL] [Abstract][Full Text] [Related]
16. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract][Full Text] [Related]
17. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
Ferrero S; Grimaldi D; Genuardi E; Drandi D; Zaccaria GM; Alessandria B; Ghislieri M; Ferrante M; Evangelista A; Mantoan B; De Luca G; Stefani PM; Benedetti F; Casaroli I; Zanni M; Castellino C; Pavone V; Petrini M; Re F; Hohaus S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M
Blood; 2022 Sep; 140(12):1378-1389. PubMed ID: 35737911
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Torka P; Akhtar OS; Reddy NM; Baysal BE; Kader A; Groman A; Nichols J; Mavis C; Tario JD; Block AW; Sait SNJ; Ghione P; Sundaram S; Przespolewski ER; Mohr A; Lund I; Kostrewa J; McWhite K; DeMarco J; Johnson M; Darrall A; Thomas-Talley RN; Wallace PK; Neppalli V; Hutson A; Hernandez-Ilizaliturri FJ
Cancer; 2022 Apr; 128(8):1595-1604. PubMed ID: 35157306
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance.
Pott C
Semin Hematol; 2011 Jul; 48(3):172-84. PubMed ID: 21782059
[TBL] [Abstract][Full Text] [Related]
20. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Short NJ; Zhou S; Fu C; Berry DA; Walter RB; Freeman SD; Hourigan CS; Huang X; Nogueras Gonzalez G; Hwang H; Qi X; Kantarjian H; Ravandi F
JAMA Oncol; 2020 Dec; 6(12):1890-1899. PubMed ID: 33030517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
